Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vornado, Ken Griffin and Rudin Close 350 Park Avenue Joint Venture

Vornado, Ken Griffin and Rudin Close 350 Park Avenue Joint Venture

BitgetBitget2026/10/21 13:10
  • Vornado Realty Trust closed a joint venture with Ken Griffin and Rudin to develop 350 Park Avenue in Manhattan.
  • A Griffin affiliate owns 60% of the venture, with Vornado holding 36% and Rudin 4%.
  • The venture secured a $3.3 billion construction loan.
  • Citadel Enterprise Americas signed a 1.05 million-square-foot anchor lease; 850,000 square feet will be available to the market.
  • Construction is underway on the 66-story tower, which will deliver more than 1.9 million square feet.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vornado Realty Trust published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210909PRIMZONEFULLFEED9850439) on October 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks